Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* 18 - 65 years~* Positive for HSV-1 and/or -2 (as determined by serology testing in course of study)~* Initial infection \> 1 year ago~* ≥ 6 recurrences in the last year (or in the year prior to a recent prophylactic therapy)~* ≥ 2 recurrences during the six-month baseline period~Exclusion Criteria:~* Known or suspected allergy or intolerability to PEG~* Prophylactic antiviral drugs, virostatic agents, cytostatics, immunomodulatory drugs and steroids within less than 14 days prior to baseline period, or plan to take such drugs during the trial~* Pregnancy and/or breast-feeding~* History of malignant diseases (described in chapter 7.2)~* Known or suspected non-compliance to study protocol~* Participation in another investigational drug study in the last 30 days prior to baseline period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PEG-Formulation (Type: EXPERIMENTAL): PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).